Venturium has selected JAL Therapeutics to pitch its differentiated target with novel small-molecule inhibitors for Alzheimer’s disease at Venturium Spring ’26.
JAL Therapeutics presented at the First Look SoCal Innovation Showcase, held at the Skirball Cultural Center in Los Angeles. The event, organized by the Alliance for Southern California
JAL Therapeutics, a pioneering life sciences company focused on developing innovative treatments for Alzheimer’s disease and other chronic conditions, has joined the Academic Venture Exchange (AVX). As a
JAL Therapeutics presented at the California Life Sciences (CLS) Innovation Showcase held at Bakar Labs on the campus of UC Berkeley. The event was an opportunity to connect with industry leaders, investors and entrepreneurs to culminate the company’s participation in the FAST California advisory program.
JAL Therapeutics’ highly inhibitory, hyperselective, covalent approach to butyrylcholinesterase (BChE) inhibition may become the new frontier for treating and preventing Alzheimer’s disease, CNS disorders and other chronic conditions.
JAL Therapeutics’ highly inhibitory, hyperselective, covalent approach to butyrylcholinesterase (BChE) inhibition may become the new frontier for treating and preventing Alzheimer’s disease, CNS disorders and other chronic conditions.
Venturium has selected JAL Therapeutics to pitch its differentiated target with novel small-molecule inhibitors for Alzheimer’s disease at Venturium Spring ’26.
JAL Therapeutics presented at the First Look SoCal Innovation Showcase, held at the Skirball Cultural Center in Los Angeles. The event, organized by the Alliance for Southern California Innovation, provided
JAL Therapeutics, a pioneering life sciences company focused on developing innovative treatments for Alzheimer’s disease and other chronic conditions, has joined the Academic Venture Exchange (AVX). As a non-profit cooperative,
JAL Therapeutics presented at the California Life Sciences (CLS) Innovation Showcase held at Bakar Labs on the campus of UC Berkeley. The event was an opportunity to connect with industry leaders, investors and entrepreneurs to culminate the company’s participation in the FAST California advisory program.
JAL Therapeutics’ highly inhibitory, hyperselective, covalent approach to butyrylcholinesterase (BChE) inhibition may become the new frontier for treating and preventing Alzheimer’s disease, CNS disorders and other chronic conditions.
JAL Therapeutics’ highly inhibitory, hyperselective, covalent approach to butyrylcholinesterase (BChE) inhibition may become the new frontier for treating and preventing Alzheimer’s disease, CNS disorders and other chronic conditions.